Department of Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Clin J Pain. 2013 Jul;29(7):570-6. doi: 10.1097/AJP.0b013e318270f97b.
It is questionable whether the stress response to surgery is necessary. The objective of this study was to evaluate the effectiveness of postoperative analgesia on energy metabolism and compare cyclooxygenase-2 selective inhibitor with tramadol in postoperative pain management after major abdominal surgery.
A total of 112 patients undergoing major abdominal surgery were randomly assigned to one of the 4 treatment groups before surgery. Then, patients were scheduled to receive different analgesic drugs after surgery: group parecoxib/control received intravenous parecoxib (40 mg bid) for 3 days; group parecoxib/celecoxib received intravenous parecoxib (40 mg bid) for 3 days and continued oral celecoxib (0.2 mg bid) for 4 days; group tramadol/control received intravenous tramadol (0.1 g tid) for 3 days; and group tramadol/tramadol received intravenous tramadol (0.1 g tid) for 3 days and continued oral tramadol (0.1 g tid) for 4 days.
Group tramadol/tramadol showed much lower rest energy expenditure 1 week after surgery (P<0.05). The measured rest energy expenditure was significantly lower in patients treated with analgesic drugs administered from day 4 to 7 after surgery relative to control group (P<0.01). From the fourth day after surgery, groups parecoxib/celecoxib and tramadol/tramadol showed significantly lower pain intensity ratings compared with groups parecoxib/control and tramadol/control during leg raising (P<0.05).
These results confirm that sufficient postoperative analgesia may be efficient to reduce some of the stress responses to operative trauma. In addition, intravenous parecoxib (40 mg bid) followed by oral celecoxib (0.2 g bid) is as effective as intravenous tramadol (0.1 g tid) with continued oral tramadol (0.1 g tid) after major abdominal surgery.
手术引起的应激反应是否必要仍存在争议。本研究旨在评估术后镇痛在能量代谢方面的效果,并比较环氧化酶-2 选择性抑制剂与曲马多用于大型腹部手术后的术后疼痛管理。
112 例行大型腹部手术的患者在术前被随机分为 4 个治疗组之一。然后,患者在术后接受不同的镇痛药物治疗:帕瑞昔布/对照组接受静脉注射帕瑞昔布(40mg,bid),共 3 天;帕瑞昔布/塞来昔布组接受静脉注射帕瑞昔布(40mg,bid),共 3 天,继以塞来昔布(0.2mg,bid)口服,共 4 天;曲马多/对照组接受静脉注射曲马多(0.1g,tid),共 3 天;曲马多/曲马多组接受静脉注射曲马多(0.1g,tid),共 3 天,继以曲马多(0.1g,tid)口服,共 4 天。
术后 1 周时,曲马多/曲马多组的静息能量消耗明显较低(P<0.05)。与对照组相比,术后第 4 天至第 7 天接受镇痛药物治疗的患者静息能量消耗明显较低(P<0.01)。从术后第 4 天开始,帕瑞昔布/塞来昔布组和曲马多/曲马多组在抬腿时的疼痛强度评分明显低于帕瑞昔布/对照组和曲马多/对照组(P<0.05)。
这些结果证实,充分的术后镇痛可能有效减少手术创伤引起的应激反应的某些方面。此外,在大型腹部手术后,静脉注射帕瑞昔布(40mg,bid)继以口服塞来昔布(0.2g,bid)与静脉注射曲马多(0.1g,tid)持续口服曲马多(0.1g,tid)一样有效。